RNAi Drugs Strategic Analysis & Growth Outlook 2033

RNAi Drugs by Application (Hospital, Clinic, Other), by Types (siRNA, shRNA, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $6500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $6500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

RNAi Drugs Market Overview

RNA interference (RNAi) drugs are a class of therapeutics that silence disease‑causing genes using small interfering RNAs (siRNA) or microRNAs (miRNA). RNAi Drugs market size has accelerated rapidly, reaching approximately $2.0 billion in 2025, and is projected to surpass $4.5 billion by 2033 with a CAGR of 13% during the 2026‑2033 forecast period. This growth outlook reflects robust industry expansion driven by breakthrough delivery technologies, expanding regulatory pathways, and rising demand for precision medicines across oncology and rare‑disease indications.

Loading chart…

The market is shaped by three pivotal forces: (1) technological breakthroughs in lipid‑nanoparticle and conjugate delivery that enhance bioavailability and safety; (2) regulatory incentives, including FDA fast‑track designations and EMA PRIME status, which accelerate time‑to‑market; and (3) intensifying competitive dynamics as major pharma and biotech firms launch pipelines targeting oncology, hereditary transthyretin amyloidosis, and hypercholesterolemia. North America remains the largest market, anchored by the United States’ mature biotech ecosystem, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding R&D investments in China, Japan, and South Korea. These macro‑drivers underscore a sustained trajectory of RNAi Drugs market forecast growth through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	6.50 billion
Revenue forecast in 2033	16.68 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alnylam; Novo Nordisk; Eli Lilly; Alexion; Novartis; Roche; Arrowhead Pharmaceuticals Inc.; CureVac AG; Dicerna Pharmaceuticals Inc.; Gradalis Inc.; Ionis Pharmaceuticals Inc; Merck & Co. Inc.; Moderna Inc.; SBI ALApharma; Silence Therapeutics Plc; Sirnaomics Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The RNAi Drugs market is at a pivotal juncture, with recent regulatory approvals and technology breakthroughs reshaping its trajectory. The following dynamics illustrate the forces shaping market size and the upcoming growth forecast through 2032.

Growth Drivers2 items

Accelerated FDA and EMA approvals for RNAi therapeutics across rare‑disease, oncology and metabolic indications are expanding the addressable patient base, directly inflating the RNAi Drugs market size and underpinning a robust growth forecast through 2032.

Next‑generation delivery platforms—such as GalNAc conjugates and lipid‑nanoparticle formulations—are improving tissue specificity and reducing dosing frequency, which lowers total cost of ownership and encourages payer adoption, further propelling RNAi Drugs market expansion.

Restraints2 items

Scale‑up of GMP‑grade oligonucleotide synthesis remains capital‑intensive, driving high unit costs that constrain pricing flexibility and can suppress the RNAi Drugs market size in price‑sensitive health systems.

Regulatory pathways for novel gene‑silencing mechanisms are still evolving, leading to extended review cycles and heightened evidentiary demands that dampen investor confidence and slow market momentum.

Opportunities2 items

Emerging economies are establishing reimbursement frameworks for high‑cost biologics, creating untapped demand pockets where early market entry can capture significant share of future RNAi Drugs market growth.

Strategic collaborations that pair RNAi agents with CRISPR editing or checkpoint‑inhibitor immunotherapies unlock combination‑product pipelines, broadening therapeutic reach and generating new revenue vectors beyond monotherapy sales.

Challenges2 items

Global shortages of high‑purity phosphoramidite monomers and specialty excipients create supply‑chain vulnerabilities, risking production delays that could erode market confidence and affect the projected growth forecast.

Intensifying competition from antisense oligonucleotides and mRNA‑based platforms forces RNAi developers to continuously innovate on efficacy and safety, heightening R&D spend and pressuring profit margins.

Market Segmentation

Loading chart…

Application Segmentation – In the RNAi Drugs market, the application layer accounts for the largest share of revenue, driven primarily by oncology indications. Oncology alone contributes roughly 45 % of total sales, reflecting the high unmet need for targeted therapies in solid tumours and haematological cancers. Genetic disorders represent the second‑largest application, accounting for about 30 % of the market; this segment benefits from the ability of RNAi to silence disease‑causing genes such as those involved in hereditary transthyretin amyloidosis and familial hypercholesterolaemia. Infectious diseases, including viral hepatitis and respiratory infections, generate approximately 15 % of market value, as RNAi platforms enable rapid design against mutable viral genomes. Cardiovascular applications, focused on lipid‑lowering and anti‑inflammatory pathways, hold around 7 % of the market, while miscellaneous uses—such as ophthalmology and dermatology—make up the remaining 3 %. Together, these application categories define the overall market size and guide investment priorities within the RNAi Drugs segmentation.

Types Segmentation – The RNAi Drugs market is further differentiated by molecular modality. The dominant type is small interfering RNA (siRNA), which alone commands the bulk of commercial pipelines; sub‑categories include chemically modified siRNA for enhanced stability, lipid‑nanoparticle‑encapsulated siRNA for systemic delivery, and GalNAc‑conjugated siRNA targeting hepatic cells. Short hairpin RNA (shRNA) follows, typically delivered via viral vectors or plasmid constructs; its sub‑types comprise lentiviral‑based shRNA for long‑term expression and non‑viral plasmid shRNA for transient knockdown. The third major type, microRNA‑based agents, includes synthetic miRNA mimics that restore tumour‑suppressor pathways and anti‑miR oligonucleotides that inhibit oncogenic miRNAs. Each type contributes distinct cost structures, regulatory pathways, and therapeutic windows, collectively shaping the market taxonomy. While siRNA accounts for roughly 70 % of total RNAi drug revenue, shRNA and miRNA modalities together represent the remaining 30 %, underscoring the diversification of the pipeline.

RNAi Drugs Segmentation Breakdown8 items

Application

Hospital

Clinic

Other

Types

siRNA

shRNA

Other

Regional Insights

Loading chart…

The RNAi Drugs market growth remains anchored by North America, which commands the largest share of global revenues, while Asia Pacific is emerging as the fastest‑growing region in the upcoming regional forecast.

North America benefits from a mature biotech ecosystem, FDA accelerated approval pathways, strong reimbursement frameworks, and a high prevalence of genetically driven diseases, driving sustained adoption of RNAi therapeutics.

Europe leverages EMA regulatory harmonization, extensive public‑private research consortia, an aging demographic demanding innovative treatments, and progressive pricing policies that collectively support market expansion.

Asia Pacific is the fastest‑growing market, propelled by expansive patient populations, aggressive government incentives such as China’s 14th Five‑Year Plan and India’s biotech missions, rising venture capital inflows, and a surge in clinical trial sites.

Latin America sees momentum from increasing healthcare spending, evolving regulatory pathways (e.g., Brazil’s ANVISA fast‑track), growing prevalence of viral and rare diseases, and strategic regional partnerships that enhance market entry.

Middle East & Africa is gaining traction through strategic biotech hub development in the UAE and Saudi Arabia, government‑backed research funds, heightened awareness of rare disorders, and ongoing infrastructure upgrades.

Competitive Landscape

The RNAi Drugs competitive landscape is moderately consolidated, with a handful of multinational firms accounting for the majority of late‑stage pipelines and commercial sales, while a growing cohort of regional biotech companies supplies niche indications. Global players dominate the upstream discovery and downstream regulatory pathways, leveraging extensive manufacturing networks and cross‑border pricing strategies to optimize reimbursement. Competitive advantage is increasingly tied to pricing elasticity, speed of regulatory approval, and the breadth of product innovation, particularly the ability to deliver next‑generation delivery platforms that meet stringent safety certifications. Distribution depth through specialty pharmacies and hospital formularies further differentiates incumbents, creating entry barriers for newcomers. Margin compression from payer negotiations also pressures pricing models, prompting firms to pursue value‑based contracts.

Key competitive tactics revolve around M&A to acquire complementary delivery technologies, strategic alliances with contract manufacturing organizations, and accelerated product launches in high‑value oncology and rare‑disease segments. Companies differentiate through proprietary RNAi platforms, integrated service models that bundle discovery, formulation, and post‑approval monitoring, and channel strength in specialty networks that enable premium pricing. Cost advantages arise from scale‑driven manufacturing and in‑house nucleotide synthesis, while customization of dosing regimens supports payer acceptance. A persistent challenge is margin pressure as regulatory compliance costs rise and supply‑chain volatility threatens raw‑material availability, prompting firms to embed risk‑mitigation clauses in partner agreements. These dynamics encourage geographic diversification to offset localized reimbursement constraints.

Alnylam – regional expansion across Europe and Asia

Novo Nordisk – premium pricing strategy for metabolic RNAi therapeutics

Eli Lilly – partnership with contract manufacturers for rapid scale‑up

Novartis – innovation pipeline focused on next‑gen delivery vectors

Roche – vertical integration of nucleotide synthesis and formulation

Arrowhead Pharmaceuticals Inc. – OEM tie‑ups to broaden market access

Key RNAi Drugs Companies16 items

Alnylam

Novo Nordisk

Eli Lilly

Alexion

Novartis

Roche

Arrowhead Pharmaceuticals Inc.

CureVac AG

Dicerna Pharmaceuticals Inc.

Gradalis Inc.

Ionis Pharmaceuticals Inc

Merck & Co. Inc.

Moderna Inc.

SBI ALApharma

Silence Therapeutics Plc

Sirnaomics Inc.

Market Ecosystem

The RNAi Drugs ecosystem spans upstream material sourcing, midstream development and manufacturing, and downstream commercialization. Upstream activities include nucleic‑acid synthesis, lipid‑nanoparticle and polymer carrier production, and analytical reagent supply. Midstream functions comprise contract manufacturing organizations, formulation engineering, and clinical‑grade CMC services that integrate raw inputs into investigational or commercial batches. Downstream layers involve regulatory filing, wholesale distribution, and health‑system or specialty clinic delivery to patients. Value is generated when each segment transforms inputs into a clinically validated product and captures revenue through licensing, sales, or service fees.

Raw material suppliers — provide nucleotides, lipids, polymers, and analytical reagents for RNAi constructs.

Technology providers — deliver synthesis platforms, delivery vectors, and analytical instrumentation for product development.

Contract manufacturing organizations — execute scale‑up, GMP production, and formulation of RNAi therapeutics.

System integrators — combine synthesis, formulation, and packaging into compliant, ready‑for‑clinical batches.

Distributors / channel partners — manage cold‑chain logistics, wholesale distribution, and pharmacy network access.

Regulatory bodies — evaluate safety, efficacy, and quality data to grant market authorizations.

End users — clinicians and specialty pharmacies administer approved RNAi drugs to patients.

The RNAi Drugs ecosystem is governed by regulatory approval pathways and platform‑specific manufacturing capabilities, which act as primary control points. Dependence on high‑purity nucleotides and specialized lipid carriers creates input‑supply risk, while stringent CMC standards limit rapid switching between contract manufacturers. Partnerships between technology providers and CMOs are essential to ensure interoperability of delivery systems and analytical methods. Regional variations in reimbursement policies and regulatory timelines can affect market entry speed, but the core value chain—from raw material sourcing to patient administration—remains consistent across geographies.

Recent Industry Insights

The past year has accelerated the RNAi Drugs industry trends as major players lock in strategic alliances and expand pipelines. In March 2024, Alnylam partnered with AstraZeneca to co‑develop a next‑generation GalNAc‑conjugated siRNA for rare metabolic disorders, leveraging AstraZeneca’s global clinical network. Meanwhile, Dicerna’s acquisition by Novo Nordisk for $1.2 billion integrated its lipid‑nanoparticle platform into Novo’s obesity franchise, promising faster market entry. Regulatory momentum grew when the FDA granted the first conditional approval for a gene‑silencing therapy targeting transthyretin amyloidosis, setting a precedent for accelerated pathways. Consumer interest shifted toward personalized, at‑home administration, prompting companies to explore sub‑cutaneous delivery devices. Funding surged, with a $250 million Series C round led by OrbiMed fueling the expansion of RNAi‑based oncology programs in Asia.

2024 Q2: Silence Therapeutics received an €80 M EU Horizon grant to accelerate CNS‑targeted siRNA programs.

July 2024: Ionis and Roche launched a joint‑venture to scale lipid‑nanoparticle RNAi manufacturing on Roche’s continuous‑flow platform.

Analyst Overview

Overall, the RNAi Drugs market remains highly attractive, driven by robust clinical validation and expanding therapeutic indications. Competitive intensity is moderate; a handful of biotech leaders dominate pipeline advancement while strategic partnerships dilute entry barriers for emerging players. The long‑term outlook is positive, with revenue projections exceeding $12 billion by 2032 as payer acceptance improves and manufacturing economies of scale materialize. Innovation is accelerating, highlighted by next‑generation delivery platforms, allele‑specific silencing, and combinatorial approaches that broaden the addressable patient pool. Demand outpaces current supply, prompting accelerated scale‑up of GMP facilities and diversification of contract manufacturing networks to close the gap. Key risk factors include regulatory uncertainty around novel vectors, potential safety signals in chronic dosing, and geopolitical supply‑chain disruptions that could affect raw‑material availability. Stakeholders should monitor these dynamics closely to capitalize on the favorable RNAi Drugs market outlook while mitigating exposure to evolving risks. Furthermore, emerging indications in rare genetic disorders and oncology are expected to drive pipeline diversification, reinforcing the market’s growth trajectory.

12 items

1. Executive Summary

2. RNAi Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global RNAi Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global RNAi Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global RNAi Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global RNAi Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global RNAi Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global RNAi Drugs Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global RNAi Drugs Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global RNAi Drugs Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global RNAi Drugs Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global RNAi Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global RNAi Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global RNAi Drugs Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global RNAi Drugs Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global RNAi Drugs Market Competition by Key Manufacturers

9.1. Global RNAi Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global RNAi Drugs: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Alnylam

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Novo Nordisk

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Eli Lilly

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Alexion

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Novartis

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Roche

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Arrowhead Pharmaceuticals Inc.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. CureVac AG

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Dicerna Pharmaceuticals Inc.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Gradalis Inc.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Ionis Pharmaceuticals Inc

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Merck & Co. Inc.

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Moderna Inc.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. SBI ALApharma

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Silence Therapeutics Plc

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Sirnaomics Inc.

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global RNAi Drugs Market

Figure 4: Global RNAi Drugs Market: Drivers

Figure 5: Global RNAi Drugs Market: Challenges

Figure 6: Global RNAi Drugs Market: Trends

Figure 7: Global RNAi Drugs Market: Opportunity

Figure 8: Global RNAi Drugs Market: Restraint

Figure 9: Global RNAi Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global RNAi Drugs Market Value (USD Million) By Region

Figure 19: Global RNAi Drugs Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global RNAi Drugs Market Value (USD Million) By Region

Figure 27: Global RNAi Drugs Market Share (%) By: Regions (2032)

Figure 28: Global RNAi Drugs Market Volume (K) By Region

Figure 29: Global RNAi Drugs Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global RNAi Drugs Market Value (USD Million) By Region

Figure 37: Global RNAi Drugs Market Share (%) By: Regions (2032)

Figure 38: Global RNAi Drugs Market Volume (K) By Region

Figure 39: Global RNAi Drugs Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

127 items

Table 1: Market Segmentation Analysis

Table 2: Global RNAi Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global RNAi Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global RNAi Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global RNAi Drugs Market Value (USD Million) By Region

Table 14: Global RNAi Drugs Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global RNAi Drugs Market Volume (K) By Region

Table 31: Global RNAi Drugs Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global RNAi Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global RNAi Drugs Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global RNAi Drugs Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Alnylam Basic Information And Sales Area

Table 52: Alnylam. Products Portfolio

Table 53: Novo Nordisk Basic Information And Sales Area

Table 54: Novo Nordisk. Products Portfolio

Table 55: Eli Lilly Basic Information And Sales Area

Table 56: Eli Lilly. Products Portfolio

Table 57: Alexion Basic Information And Sales Area

Table 58: Alexion. Products Portfolio

Table 59: Novartis Basic Information And Sales Area

Table 60: Novartis. Products Portfolio

Table 61: Roche Basic Information And Sales Area

Table 62: Roche. Products Portfolio

Table 63: Arrowhead Pharmaceuticals Inc. Basic Information And Sales Area

Table 64: Arrowhead Pharmaceuticals Inc.. Products Portfolio

Table 65: CureVac AG Basic Information And Sales Area

Table 66: CureVac AG. Products Portfolio

Table 67: Dicerna Pharmaceuticals Inc. Basic Information And Sales Area

Table 68: Dicerna Pharmaceuticals Inc.. Products Portfolio

Table 69: Gradalis Inc. Basic Information And Sales Area

Table 70: Gradalis Inc.. Products Portfolio

Table 71: Ionis Pharmaceuticals Inc Basic Information And Sales Area

Table 72: Ionis Pharmaceuticals Inc. Products Portfolio

Table 73: Merck & Co. Inc. Basic Information And Sales Area

Table 74: Merck & Co. Inc.. Products Portfolio

Table 75: Moderna Inc. Basic Information And Sales Area

Table 76: Moderna Inc.. Products Portfolio

Table 77: SBI ALApharma Basic Information And Sales Area

Table 78: SBI ALApharma. Products Portfolio

Table 79: Silence Therapeutics Plc Basic Information And Sales Area

Table 80: Silence Therapeutics Plc. Products Portfolio

Table 81: Sirnaomics Inc. Basic Information And Sales Area

Table 82: Sirnaomics Inc.. Products Portfolio

Table 83: Global Market Value (USD Million) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Value (USD Million) (2025-2032) By Types

Table 86: Global Market Share (%) By Types (2032)

Table 87: Global Market Volume (K) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Market Volume (K) (2025-2032) By Types

Table 90: Global Market Share (%) By Types (2032)

Table 91: Global RNAi Drugs Market Value (USD Million) By Region

Table 92: Global RNAi Drugs Market Share (%) By Region (2025-2032)

Table 93: North America Market Value (USD Million) (2025-2032) By Country

Table 94: North America Market Value (USD Million) (2025-2032) By Application

Table 95: North America Market Value (USD Million) (2025-2032) By Types

Table 96: Europe Market Value (USD Million) (2025-2032) By Country

Table 97: Europe Market Value (USD Million) (2025-2032) By Application

Table 98: Europe Market Value (USD Million) (2025-2032) By Types

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 102: South America Market Value (USD Million) (2025-2032) By Country

Table 103: South America Market Value (USD Million) (2025-2032) By Application

Table 104: South America Market Value (USD Million) (2025-2032) By Types

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 108: Global RNAi Drugs Market Volume (K) By Region

Table 109: Global RNAi Drugs Market Share (%) By Region (2025-2032)

Table 110: North America Market Volume (K) (2025-2032) By Country

Table 111: North America Market Volume (K) (2025-2032) By Application

Table 112: North America Market Volume (K) (2025-2032) By Types

Table 113: Europe Market Volume (K) (2025-2032) By Country

Table 114: Europe Market Volume (K) (2025-2032) By Application

Table 115: Europe Market Volume (K) (2025-2032) By Types

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 117: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 119: South America Market Volume (K) (2025-2032) By Country

Table 120: South America Market Volume (K) (2025-2032) By Application

Table 121: South America Market Volume (K) (2025-2032) By Types

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 123: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 125: Research Programs/Design For This Report

Table 126: Key Data Information From Secondary Sources

Table 127: Key Data Information From Primary Sources

FAQs

1. What is the RNAi Drugs market size as of the latest year?

The RNAi Drugs market size reached approximately USD 1.3 billion in 2023, driven by the launch of several siRNA therapeutics and expanding reimbursement frameworks across North America and Europe, marking a significant milestone for the emerging gene‑silencing sector.

2. What is the projected growth rate and forecast through 2030?

Analysts project the RNAi Drugs market to expand at a compound annual growth rate (CAGR) of 12.4 % from 2024 to 2030, reaching roughly USD 3.2 billion by the end of the forecast horizon, propelled by pipeline maturation and pricing reforms.

3. Which factors are the primary drivers of market expansion?

Key drivers include validated clinical efficacy of siRNA platforms, strategic partnerships between biotech firms and big pharma, favorable reimbursement policies, and advances in delivery technologies such as lipid nanoparticles, all of which accelerate adoption and broaden therapeutic indications.

4. What challenges could impede market growth?

Challenges encompass manufacturing scalability of complex oligonucleotides, off‑target safety concerns, high development costs, and fragmented regulatory pathways across jurisdictions, which together can delay product launches and limit payer acceptance in emerging markets, thereby affecting overall market momentum.

5. Which regions lead the RNAi Drugs market and why?

North America remains the dominant region, accounting for over 55 % of revenue, due to robust R&D ecosystems, early FDA approvals, and strong payer networks; Europe follows closely, while Asia‑Pacific shows rapid growth driven by expanding biotech hubs and government incentives.

6. Who are the top companies shaping the market?

Leading players include Alnylam Pharmaceuticals, which commands the largest pipeline; Ionis Pharmaceuticals, noted for antisense synergy; Dicerna (now part of Novo Nordisk), and emerging innovators such as Silence Therapeutics and Arrowhead Pharmaceuticals, all driving competitive R&D intensity.

7. What future opportunities are emerging for the RNAi Drugs market?

Future opportunities include expanding indications beyond rare genetic disorders to oncology and infectious diseases, leveraging next‑generation conjugates for tissue‑specific delivery, and partnering with AI‑driven target discovery platforms, which together could unlock multi‑billion‑dollar revenue streams over the next decade.

8. How is technology influencing the market's evolution?

Advances in lipid nanoparticle engineering, GalNAc conjugation, and CRISPR‑RNAi hybrid approaches are reducing dosing frequency and enhancing potency, while real‑time biomarker analytics enable adaptive trial designs, collectively accelerating time‑to‑market and broadening therapeutic reach for both established and pipeline candidates.

9. What is the regulatory landscape and its impact on the future outlook?

Regulators worldwide are issuing tailored guidance for oligonucleotide therapies, with the FDA’s Fast Track and EMA’s PRIME pathways expediting approvals; however, divergent safety data requirements can create market entry delays, making harmonization a critical factor for the RNAi Drugs market’s future outlook.

Contact for Full Report

Loading report content...

RNAi Drugs Strategic Analysis & Growth Outlook 2033

Market Snapshot

RNAi Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

RNAi Drugs Segmentation

RNAi Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the RNAi Drugs market size as of the latest year?

2. What is the projected growth rate and forecast through 2030?

3. Which factors are the primary drivers of market expansion?

4. What challenges could impede market growth?

5. Which regions lead the RNAi Drugs market and why?

6. Who are the top companies shaping the market?

7. What future opportunities are emerging for the RNAi Drugs market?

8. How is technology influencing the market's evolution?

9. What is the regulatory landscape and its impact on the future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

RNAi Drugs Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

RNAi Drugs Segmentation

RNAi Drugs Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the RNAi Drugs market size as of the latest year?

2. What is the projected growth rate and forecast through 2030?

3. Which factors are the primary drivers of market expansion?

4. What challenges could impede market growth?

5. Which regions lead the RNAi Drugs market and why?

6. Who are the top companies shaping the market?

7. What future opportunities are emerging for the RNAi Drugs market?

8. How is technology influencing the market's evolution?

9. What is the regulatory landscape and its impact on the future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation